Figure 1. Preclinical and clinical studies that drove CAR-based T cell therapeutic development. About 20 years of cumulative work in academic centers has driven adoptive T cell therapies featuring chimeric antigen receptors (CARs) into the clinic and caught the attention of numerous biotechs and pharmas. Clinical studies are noted in blue.